Skip to content
06/16/2026
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Our Profile on PRLog
Merlintrader Trading Pub

Merlintrader Trading Pub

Biotech catalyst news and analysis. FDA PDUFA tracker

DISCLAIMER — Educational content only. Not financial advice. Stocks can be volatile and may cause capital loss.
Read Disclaimer
Primary Menu
  • Merlintrader
    • About Merlintrader
    • Merlintrader Blog
    • Daily Briefing
    • Daily Watchlist
    • Discord
    • Latest News
    • Small & Medium Caps
    • CHARTSWATCHER 10% OFF !
    • Disclaimer
  • Cannabis Stocks Hub 2026
    • Cannabis Stocks HUB 2026: A Possible Reset for a Broken Sector $MSOS, $TLRY, $CGC, $CRON, $ACB
    • Tilray Brands (Nasdaq: $TLRY): Cannabis, Beverage and Medical Cannabis Stock Hub
  • Space, Defense & AI Hub 2026
    • BlackSky Technology Inc. (NYSE: $BKSY) Stock Hub
    • BigBear.ai Holdings (NYSE: $BBAI)
    • Castellum, Inc. (NYSE American: $CTM) Stock Hub
    • Intuitive Machines (Nasdaq: $LUNR) Stock Hub
    • Ondas Holdings (NASDAQ: $ONDS) Stock Hub
    • Palladyne AI Corp. (Nasdaq: $PDYN) Stock Hub
    • Planet Labs PBC (NYSE: $PL)
    • POET Technologies (NASDAQ: $POET): Company Story,
    • Red Cat Holdings (NASDAQ: $RCAT)
    • Redwire Corporation (NYSE: $RDW) Stock Hub
    • Rocket Lab Corporation (Nasdaq: $RKLB) Stock Hub
    • Satellogic Inc. (Nasdaq: $SATL)
  • Biotech Stocks Hub
    • ADMA Biologics (Nasdaq: $ADMA)
    • Agios Pharmaceuticals (Nasdaq: $AGIO) Stock Hub
    • Alpha Tau Medical Ltd. (Nasdaq: $DRTS)
    • Altimmune Inc. (Nasdaq: $ALT )
    • Aquestive Therapeutics (Nasdaq: $AQST Stock Hub.
    • Ardelyx, Inc. (Nasdaq: $ARDX) Stock Hub
    • BioCryst Pharmaceuticals (Nasdaq: $BCRX) Stock Hub
    • Capricor Therapeutics (Nasdaq: $CAPR) Stock Hub
    • Corcept Therapeutics $CORT Stock Hub
    • CorMedix Therapeutics (Nasdaq: $CRMD) Stock Hub
    • Cytokinetics, Incorporated (Nasdaq: $CYTK)
    • Fate Therapeutics (Nasdaq: $FATE): Stock Hub
    • Geron Corporation (Nasdaq: $GERN) Stock Hub
    • ImmunityBio, Inc. (Nasdaq: $IBRX) Stock Hub
    • Iovance Biotherapeutics (Nasdaq: $IOVA)
    • MannKind Corporation (Nasdaq: $MNKD) Stock Hub
    • Microbot Medical Inc. (Nasdaq: $MBOT) Stock Hub
    • Moleculin Biotech (Nasdaq: $MBRX) Stock Hub
    • Novavax, Inc. (Nasdaq: $NVAX) Stock Hub
    • NRx Pharmaceuticals (Nasdaq: $NRXP) Stock Hub
    • Ocugen, Inc. (Nasdaq: $OCGN) Stock Hub
    • Ocular Therapeutix (Nasdaq: $OCUL) Stock Hub
    • Omeros Corporation (Nasdaq: $OMER): Stock Hub
    • Outlook Therapeutics (Nasdaq: $OTLK): Stock Hub
    • Protalix BioTherapeutics (NYSE American: $PLX) Stock Hub
    • SeaStar Medical Holding Corporation (Nasdaq: $ICU) Stock Hub
    • SELLAS Life Sciences Group (Nasdaq: $SLS) Stock Hub.
    • Summit Therapeutics (Nasdaq: $SMMT) Stock Hub
    • Travere Therapeutics (Nasdaq: $TVTX)
    • Viridian Therapeutics (Nasdaq: $VRDN)
  • FREE CATALYST CALENDAR
    • Catalyst Total Tracker
  • Merlintrader Travel Pub

Home - Editorial - Fed, Inflation and Oil: Why SPY Is Trading the Energy Shock Before the June FOMC

  • Editorial

Fed, Inflation and Oil: Why SPY Is Trading the Energy Shock Before the June FOMC

The market is not only reacting to lower crude prices. It is repricing the inflation path, the Federal Reserve’s room for patience, and the durability of the equity rally just as the June 16–17 FOMC meeting begins.
20 views
Spy oil inflation
Macro Market Watch Fed • Inflation • Oil • SPY
“`

Fed, Inflation and Oil: Why SPY Is Trading the Energy Shock Before the June FOMC

The market is not only reacting to lower crude prices. It is repricing the inflation path, the Federal Reserve’s room for patience, and the durability of the equity rally just as the June 16–17 FOMC meeting begins.

Merlintrader Market Analysis Updated: June 16, 2026 Educational content only
SPY daily chart from Finviz
Fed Meeting June 16–17
May CPI +4.2% YoY
May Core CPI +2.9% YoY
Oil Setup Relief, not clarity

The most important market story this morning is not simply that oil is falling. The real story is that crude oil is now acting as the transmission belt between geopolitics, inflation expectations, Federal Reserve policy and the direction of the S&P 500. For SPY, this is exactly the kind of macro junction that can turn a normal market session into a broader repricing event.

The timing matters. The Federal Reserve begins its June 16–17 policy meeting with investors already focused on a difficult inflation backdrop. The latest U.S. CPI report showed that consumer prices rose 0.5% in May on a seasonally adjusted basis, while the all-items index increased 4.2% over the prior twelve months. The report also made clear that energy was not a side issue: the energy index rose 3.9% in May and accounted for more than sixty percent of the monthly all-items increase.

That is why the oil move matters so much for equities. A sharp decline in crude can immediately soften the market’s fear that energy inflation will keep feeding into gasoline, transportation, airline fares, logistics, consumer expectations and corporate margins. But it does not automatically solve the inflation problem. Core CPI, which excludes food and energy, still rose 2.9% year over year in May, and shelter remained sticky enough to keep the Federal Reserve cautious.

The key market question: Is the oil decline a durable disinflationary relief signal, or just a temporary geopolitical repricing before the Fed reminds investors that one softer commodity move is not enough to declare victory?

The Fed Is Walking Into a Cleaner Oil Tape, But Not a Clean Inflation Tape

The June FOMC meeting is important because it comes with updated projections. This is not just a routine statement day. It is a meeting associated with the Summary of Economic Projections, which means investors will be reading the Fed’s rate path, inflation assumptions, growth view and unemployment projections as carefully as the headline decision itself.

The market does not expect the Fed to suddenly turn dovish because oil dropped for a few sessions. The more realistic question is whether lower oil can reduce pressure on policymakers to sound even more hawkish. In recent weeks, the inflation conversation had become more uncomfortable because energy prices were feeding directly into headline CPI and into the political and psychological perception of inflation.

If crude continues lower, the Fed can acknowledge the relief without fully endorsing it. Policymakers generally prefer not to overreact to short-term energy swings, especially when the geopolitical situation remains unresolved. But markets do not wait for perfect confirmation. Equity traders are already trying to price what a softer oil path could mean for the next CPI prints, Treasury yields, real rates and earnings expectations.

For SPY, that creates a delicate but potentially supportive setup. Lower oil can help the broad index through three channels: reduced inflation pressure, better consumer purchasing power and improved margin assumptions for energy-sensitive sectors. The problem is that those same benefits may be capped if the Fed uses the June meeting to push back against premature easing expectations.

Oil Is the Macro Swing Factor

Crude oil has become the market’s most important short-term macro variable because the recent geopolitical shock hit precisely where inflation is most visible to households and traders: energy. Brent and WTI moved sharply lower as markets priced a preliminary U.S.-Iran framework and the possibility of a gradual restoration of energy flows through the Strait of Hormuz, while the physical normalization of shipments, insurance costs and regional security remain key uncertainties.

The immediate equity reaction is easy to understand. If the market believes the worst of the supply disruption risk is fading, then the inflation premium embedded in oil, yields and defensive positioning can unwind. That tends to support broader risk appetite and can be especially helpful for sectors hurt by high fuel costs.

Airlines, transports, consumer discretionary names and parts of industrials are obvious beneficiaries when fuel pressure eases. Technology and growth stocks can also benefit indirectly if lower energy reduces the probability of a more aggressive Fed stance. Small caps may participate if yields calm down, though they remain more sensitive to financing costs and economic growth expectations than mega-cap technology.

Energy stocks are the other side of the trade. Lower oil can pressure producers, refiners and oilfield services if investors begin to price a more normal supply environment. That does not mean the entire energy sector becomes unattractive from a fundamental perspective, but it does mean the near-term narrative shifts from scarcity premium to supply normalization risk.

Important risk: the oil relief trade depends on the market believing that supply flows can normalize. If the Strait of Hormuz reopening process becomes messy, delayed or politically unstable, crude could quickly regain a risk premium and the inflation narrative could tighten again.

SPY Is Trading a Policy Relief Scenario, Not a Full All-Clear

SPY is the cleanest market thermometer here because it captures the broad equity reaction across technology, financials, industrials, healthcare, consumer sectors and energy. When SPY rises on falling oil, the message is not simply that investors like cheaper crude. The message is that investors are reducing the probability of a more damaging inflation-policy spiral.

The bullish interpretation is straightforward: oil falls, headline CPI pressure cools, Treasury yields stabilize, the Fed has less reason to tighten further, and earnings multiples can hold. In that scenario, the S&P 500 can continue to absorb a cautious Fed because the market sees the inflation path improving in real time.

The bearish interpretation is also important. If the Fed focuses on the fact that inflation is still above target, core inflation is not collapsing, and shelter remains sticky, then the market may discover that lower oil is helpful but not enough. SPY can rally on relief, but it still needs confirmation from yields, earnings revisions and Fed language.

This is why the June press conference matters. If the Fed Chair frames the oil decline as welcome but uncertain, the market may accept that as balanced. If the Fed instead emphasizes persistent inflation risk, upside risks to prices, strong labor data or the possibility that policy needs to stay restrictive for longer, then the rally can become more fragile.

The Inflation Read: Headline Relief Versus Core Reality

The May CPI report gives both bulls and bears something to work with. Bulls can point to the possibility that the next CPI prints may improve if gasoline and energy prices retreat from recent shock levels. Bears can point to the fact that the latest reported inflation data still showed a 4.2% annual increase in headline CPI and a 2.9% annual increase in core CPI.

The distinction matters because the Fed does not target gasoline prices directly. Energy can move headline inflation sharply, but policymakers usually look through temporary commodity shocks unless they begin to affect expectations, wages or broader pricing behavior. The danger of the recent oil shock was that it risked becoming persistent enough to influence the wider inflation psychology.

A sustained oil decline would reduce that danger. It would not immediately bring inflation back to target, but it would remove one of the most visible accelerants. For consumers, gasoline prices matter because they are frequent, visible and emotionally powerful. For companies, energy costs matter because they flow through logistics, production, travel and operating margins. For the Fed, the key issue is whether those pressures become embedded.

That is why the market is treating oil as a policy input. Lower crude does not set Fed policy by itself, but it changes the distribution of outcomes. It reduces the odds of the worst inflation scenarios and gives equity investors a reason to stay constructive unless the Fed actively pushes back.

Sector Rotation: Who Benefits, Who Gets Hit

The first-order sector impact is relatively clear. Lower oil tends to help fuel-sensitive sectors and hurt energy-linked equities. But the second-order impact is more important for SPY: lower oil can support multiple expansion in long-duration growth stocks if it cools inflation expectations and yields.

Market AreaPotential Positive ReadMain Risk
SPY / S&P 500Broad risk appetite improves if oil relief reduces inflation and Fed pressure.Fed language may remain restrictive if core inflation and labor data stay firm.
QQQ / GrowthLower energy can reduce yield pressure and support long-duration equity multiples.Tech valuations remain sensitive to any hawkish Fed surprise.
IWM / Small CapsLower yields and better risk appetite can help speculative and cyclical small caps.Financing costs remain a major headwind if policy stays tight.
Airlines / TransportsFuel relief can improve margin expectations and sentiment.Demand and pricing power still matter; not all fuel relief becomes profit.
Energy StocksLong-term fundamentals may remain supported if supply normalization is slow.Near-term oil downside can pressure producers and oil-linked equities.
Biotech / Healthcare GrowthLower yields can improve appetite for long-duration catalyst stories.Fed hawkishness can still weigh heavily on cash-burning names.

The Bull Case for SPY

The bull case is that the market has just received exactly the kind of external relief it needed before a difficult Fed meeting. Inflation was uncomfortable, but a major part of the most recent monthly CPI pressure came from energy. If crude continues lower, the next inflation prints can look less threatening, and investors may begin to price a more manageable policy path.

In that scenario, SPY can hold up even if the Fed does not cut rates or sound openly dovish. The market does not need the Fed to declare victory. It only needs the Fed to avoid escalating the hawkish message. If policymakers acknowledge uncertainty but do not lean aggressively against the equity rally, the combination of lower oil, stable yields and resilient earnings expectations can keep the broader index supported.

The bull case also benefits from positioning. Geopolitical shocks often force investors into defensive trades quickly. When the immediate risk premium unwinds, those defensive positions can reverse, creating a relief bid across equities. That is especially true when the underlying economy has not yet shown clear signs of breaking.

The Bear Case for SPY

The bear case is that the market is confusing an oil repricing with a genuine inflation victory. The latest CPI data still showed inflation running above the Fed’s comfort zone. Core inflation remains sticky enough to prevent a clean dovish pivot, and the Fed may prefer to maintain credibility rather than validate a risk-asset rally too early.

There is also a geopolitical risk. The oil market is pricing better supply expectations, but the details around any normalization of flows remain critical. If negotiations stall, if enforcement becomes unclear, or if regional actors disrupt the process, oil could regain a risk premium quickly. That would bring back the inflation anxiety that equities are currently trying to move past.

The bear case is not necessarily a crash scenario. It may simply mean that SPY struggles to extend higher until the Fed event is cleared and the market receives firmer evidence that lower oil is sustainable. Relief rallies can be powerful, but they become vulnerable when they front-run policy confirmation.

What Traders Should Watch Next

The first watch item is the Fed statement and press conference on June 17. The market will look for any change in language around inflation risks, energy prices, growth, labor conditions and the expected policy path. The Summary of Economic Projections may be even more important than the rate decision itself because it will show how policymakers are thinking about the rest of 2026.

The second watch item is crude oil behavior after the first wave of relief. A one-day drop is useful, but the market needs to see whether Brent and WTI can remain lower as details around supply normalization become clearer. If oil stabilizes at lower levels, equities can treat the move as genuine macro relief. If oil snaps back, the inflation trade returns quickly.

The third watch item is Treasury yields. SPY can usually tolerate a cautious Fed better when yields are stable or falling. If yields rise despite lower oil, that would suggest the bond market is still worried about inflation, growth, fiscal supply or Fed policy. That would make the equity rally more fragile.

The fourth watch item is market breadth. A healthy SPY move should not rely only on a handful of mega-cap technology names. If transports, industrials, consumer discretionary, financials and selected small caps participate, the rally has a broader foundation. If the move stays narrow, it becomes more vulnerable to a Fed-driven reversal.

Merlintrader bottom line: lower oil gives SPY a credible relief narrative into the Fed, but the market still needs confirmation. The setup is constructive if crude stays lower and the Fed avoids a strongly hawkish tone. It becomes fragile if policymakers emphasize persistent inflation or if the oil-risk premium returns.

Bottom Line

Today’s market is trading the intersection of four forces: the Fed, inflation, oil and SPY. The oil decline is important because it attacks the most visible part of the inflation problem just as the Federal Reserve enters a projection-heavy policy meeting. That gives equities a reason to rally, but not a guarantee that the rally is safe.

For SPY, the message is balanced. The broad market can benefit from lower oil, softer inflation expectations and improved risk appetite. But the Fed still controls the tone of the next move. If the June meeting confirms that policymakers are willing to stay patient while energy pressure fades, the relief trade can extend. If the Fed signals that inflation remains too persistent and policy must stay restrictive, SPY may have already priced too much comfort.

The cleanest interpretation is this: oil has opened the door for a better equity narrative, but the Fed still decides how far the market can walk through it.

Primary and Reference Sources

  • Federal Reserve — FOMC meeting calendar: Federal Reserve FOMC Calendars
  • Federal Reserve — June 2026 calendar and press conference schedule: Federal Reserve June 2026 Calendar
  • U.S. Bureau of Labor Statistics — Consumer Price Index, May 2026: BLS CPI May 2026 PDF
  • Reuters — Oil and energy markets react to the U.S.-Iran framework and Hormuz supply-risk repricing: Reuters oil market update
  • Reuters — Wall Street reaction to U.S.-Iran deal and oil slide: Wall Street rallies as oil prices slide
Educational disclaimer: This article is for informational and educational purposes only and does not constitute investment advice, financial advice, trading advice, a recommendation to buy or sell any security, or personalized guidance. Markets involve risk, including the possible loss of capital. Readers should conduct their own research and consider their own financial situation, risk tolerance and regulatory context before making any investment or trading decision.
“`

What do you feel about this?

  • Editorial

Post navigation

Previous: The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question

Related Stories

truce Usa Iran
  • Editorial

The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question

53
The week ahead jun 15
  • Editorial

The Week Ahead: Fed Pressure, Trump Risk, SpaceX Aftershock and Small-Cap Catalysts to Watch — $SPRO $RKLB $PL

56
SPCX
  • Editorial
  • Space

SpaceX (Nasdaq: $SPCX): The Real “X Day” for Public Markets and the New Space Trade

12
Analisi delle immagini e generazione di contenuti SEO in italiano:.
  • Editorial

LILA $107M, HOOD $55M, NCLH $25M, IFF $20M and more: the 20 largest insider purchases of the last two weeks

19
Markert Crossroads
  • Editorial

Market Crossroads: SPY, Inflation, War Risk, Fed Rates and the Trump Factor

9
weekly june 6
  • Editorial

Weekly Market Recap · June 6, 2026

3

Trending Now

Fed, Inflation and Oil: Why SPY Is Trading the Energy Shock Before the June FOMC Spy oil inflation 1
  • Editorial

Fed, Inflation and Oil: Why SPY Is Trading the Energy Shock Before the June FOMC

20
The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question truce Usa Iran 2
  • Editorial

The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question

53
Celldex Therapeutics — Barzolvolimab, Mast Cells and the Revolution in Chronic Urticaria Treatmen cldx 3
  • Reports Biotech

Celldex Therapeutics — Barzolvolimab, Mast Cells and the Revolution in Chronic Urticaria Treatmen

77
Neumora Therapeutics (Nasdaq: $NMRA): Navacaprant Is Over, the Platform Story Moves to NMRA-511, NMRA-898 and NMRA-215 nmra 4
  • Reports Biotech

Neumora Therapeutics (Nasdaq: $NMRA): Navacaprant Is Over, the Platform Story Moves to NMRA-511, NMRA-898 and NMRA-215

70

Welcome to Merlintrader!
Here we share ideas, analysis and news from the biotech and small-cap world, with a special focus on the catalysts that really move the market.
If you like the content on this site, please help me by sharing it on social media and in other forums. Thank you!

✦ Disclaimer: The information provided is strictly for educational and informational purposes. This content represents independent, informational research and does not constitute regulated investment research or financial advice. I am not a licensed financial advisor or an authorized investment professional. Nothing here should be interpreted as a recommendation to buy, sell, or trade any security. If you need personalized financial advice, you should consult a qualified and authorized professional. Biotech and small-cap stocks carry significant risk, including the potential loss of all invested capital. Each user remains fully responsible for their own trading decisions. Full legal disclaimers.
✦ RunUP Biotech: Interested in understanding market dynamics around FDA catalysts and clinical trials? The RunUP Biotech strategy provides a framework for analyzing pre-event positioning, volume patterns, and risk-management approaches. Educational focus on probability and pattern structure — not predictions or guaranteed outcomes. Learn more →
✦ Support Merlintrader: This website is free and has no paywall. If you find the reports and tools useful, you can support the project via Buy Me a Coffee — it helps me cover costs and keep publishing independent analysis.
✦ Disclosure: I closed my DRTS position today, May 11, at $10.29 per share, after entering at $7.31 per share. I opened a small position in CING on May 12 at $4.90 per share. Read the full disclaimer.
```
Free research library

Explore the Merlintrader blog

Inside the site you will find hundreds of free reports, deep dives on biotech and small caps, FDA catalyst coverage, market analysis, and articles built to help readers understand what really moves these stocks.

  • Full reports on individual stocks
  • FDA, catalyst and clinical-trial analysis
  • Daily briefings, watchlists and market themes
  • A free archive updated on a regular basis
Explore the blog

Free content, readable structure, and regular updates.

Archivio gratuito

Esplora il blog Merlintrader

Nel sito trovi centinaia di report gratuiti, approfondimenti su biotech e small cap, catalyst FDA, analisi di mercato e articoli pensati per aiutare i lettori a capire meglio cosa muove davvero questi titoli.

  • Report completi su singoli titoli
  • Analisi di catalyst, FDA e trial clinici
  • Daily briefing, watchlist e temi di mercato
  • Un archivio gratuito aggiornato con regolarità
Vai al blog

Contenuti gratuiti, struttura leggibile e aggiornamenti costanti.

Merlintrader Newsletter

Stay ahead of the next catalyst

Get market notes, deep-dive updates and catalyst-focused research directly from Merlintrader.

Educational market content only. No spam. You can unsubscribe anytime.
Terms, privacy and disclaimer
DISCLAIMER — Educational content only. Not financial advice. Stocks can be volatile and may cause capital loss.
Read Disclaimer
Scanner for active traders
ChartsWatcher logo

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

ChartsWatcher platform screenshot
Recommended platform
Medved Trader logo

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Medved Trader platform dashboard
Merlintrader author

Authors: Merlintrader, Jane and Gemini

Author's note

In every piece of content I share things as I personally interpret them, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants (Jane and Gemini), which help me organise data, cross-check details and improve charts or visuals. However, any interpretation, opinion and final judgement remain entirely my own as a trader like you, not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If you spot something that looks off, feel free to let me know and I will correct it. Please do not treat this content as professional investment advice, but as one more piece of information to compare with your own research and the opinion of qualified professionals.

Donate via PayPal

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs so that the content can remain independent and freely accessible.

Buy Me a Coffee

Tools and research platforms used by Merlintrader

Below is a shortlist of tools and platforms that I personally use to follow prices, catalysts, fundamentals and sentiment. Links are provided for transparency and convenience only.

  • Finviz Elite – advanced stock screener and charting, used for heatmaps, relative performance and technical context.
  • ChartsWatcher – real-time, next-generation scanner for the US stock market. Used to monitor intraday momentum, volume spikes and colour-coded pattern alerts.
  • Stocktwits – social stream focused on tickers, used only as a sentiment and activity indicator, not as a source of investment recommendations.
  • Monica.im – AI assistant used for light reports, drafting and quick research; helps with structuring notes and first-pass analysis alongside the deep-dive work published on Merlintrader.
  • Medved Trader – professional trading and charting platform used for real-time execution, order-flow and detailed intraday analysis. No affiliate link; mentioned because it is part of the actual trading workflow.
  • Merlintrader trading Blog – the home for biotech-focused reports, dashboards and educational articles that expand on the ideas mentioned in this document.

AI usage disclosure

Content on Merlintrader may be prepared using a human + AI workflow. Drafting, editing and data organisation may be supported by generative AI tools, for example large language models provided by third-party vendors, based on prompts and instructions defined by the author. All sources are publicly available, and the final selection of data, checks, opinions and conclusions is carried out by the author, who remains fully responsible for the content.

Monica.im Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Legal disclaimer – please read carefully

Each piece of content is provided strictly for informational and educational purposes. It is not and must not be interpreted as investment advice, investment research in a regulatory sense, portfolio management, or a recommendation to buy or sell any security or financial instrument. The author is not a licensed investment advisor, not a registered broker, and not a FINRA/SEC-registered analyst or portfolio manager. Any reference to potential scenarios, price levels or catalysts is purely illustrative and reflects a personal, non-professional view based on publicly available information at the time of writing.

Nothing in any content published on Merlintrader should be considered a solicitation to the public to invest, nor an invitation to raise capital, nor a promise of profit or of capital protection. Biotech and healthcare stocks in particular can be highly volatile and speculative, especially around clinical and regulatory catalysts. Before making any investment or trading decision, always perform your own due diligence and consider consulting a qualified, regulated financial professional who can evaluate your personal situation, objectives and risk tolerance. Past performance and historical examples do not guarantee future results.

The author may hold, or may have held, long or short positions in some of the securities mentioned in Merlintrader content, and may open, close or modify such positions without notice. This potential alignment of interests may influence the tone or focus of the analysis. No position held by the author changes the fact that this content is not investment advice and should not be used as such.

Biotech Catalyst Calendar

For a broader, continuously updated view of upcoming biotech catalysts (PDUFA dates, major clinical readouts, regulatory events and key conferences), you can consult the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar

  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Our Profile on PRLog
Terms and Conditions
Cookie Policy
Privacy Policy
Merlintrader is a personal blog curated by Horacio F. Greco. Contact: info@merlintrader.com. No professional financial advice.
Do Not Sell or Share My Personal Information